
TNF TNF

13.1.1

TNF TNF 0.8mg/kg 50mg/ 2 0.4mg/kg 25mg/2 JIA

13.1.2 Infliximab

Infliximab 8 1 6mg/kg 3mg/kg/ Infliximab

13.1.3

2 1 24mg/m2/ 40mg/ JIA A

13.2

13.2.1 Abatacept

Abatacept T CTL4Ig

Abatacept 1-6mg/kg
Abatacept
TNF

13.2.2 Anakinra

Anakinra IL-1 IL-1
cryopirin CAPS
Anakinra 1-2mg/kg
5mg/kg 100mg
JIA
cryopirin CAPS

13.2.3 Canakinumab

Canakinumab 1 (IL1)
cryopirin (CAPS)
Canakinumab 1-4mg/kg
cryopirin (CAPS)

13.2.4

6 IL6
JIA 15-30kg 1-8mg/kg
30kg 12mg/kg 4-10mg/kg
JIA
JIA

13.3

rituximab (anti-CD20) tofacitinib (JAK-3 inhibitor) and other immunosuppressants. The use of these drugs is associated with an increased risk of infection and malignancy. Patients should be monitored for signs and symptoms of infection and malignancy. The use of rituximab is associated with an increased risk of hepatitis B reactivation. Patients should be screened for hepatitis B before starting treatment. The use of tofacitinib is associated with an increased risk of thrombosis. Patients should be monitored for signs and symptoms of thrombosis. The use of immunosuppressants is associated with an increased risk of opportunistic infections. Patients should be monitored for signs and symptoms of opportunistic infections.